Evidence map›Paper›PMID 32375388›Full record

Observational studyToxins2020

Health-Related Quality of Life Outcomes from Botulinum Toxin Treatment in Spasticity.

Lorenzo Pietro Roncoroni, Daniel Weiss, Leonhard Hieber, Justine Sturm, Axel Börtlein, Ingo Mayr, Matthias Appy, Benedicta Kühnler, Joachim Buchthal, Christian Dippon and 2 more

Abstract readObservational Study
In one paragraph

Observational study in Toxins, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Observational
  3. Review
  4. Article
  5. Article
  6. Observational
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lorenzo Pietro RoncoroniHertie-Institute for Clinical Brain Research, Department of Neurodegenerative Diseases, 72076 Tübingen, Germany.
Daniel WeissHertie-Institute for Clinical Brain Research, Department of Neurodegenerative Diseases, 72076 Tübingen, Germany.
Leonhard HieberHertie-Institute for Clinical Brain Research, Department of Neurodegenerative Diseases, 72076 Tübingen, Germany.
Justine SturmHertie-Institute for Clinical Brain Research, Department of Neurodegenerative Diseases, 72076 Tübingen, Germany.
Axel BörtleinNeurologische Klinik, Klinikum Stuttgart, 70174 Stuttgart, Germany.
Ingo MayrKlinik für Neurologie Sindelfingen, Krankenhaus Sindelfingen-Böblingen, 71065 Sindelfingen, Germany.
Matthias AppyBerufsausübungsgemeinschaft Dres, Matthias Appy, Wolfgang Molt, Prof. Arthur Melms und Kollegen, 70176 Stuttgart, Germany.
Benedicta KühnlerBerufsausübungsgemeinschaft Dres, Matthias Appy, Wolfgang Molt, Prof. Arthur Melms und Kollegen, 70176 Stuttgart, Germany.
Joachim BuchthalNeurologische Gemeinschaftspraxis am Seelberg, 70372 Stuttgart, Germany.
Christian DipponNeurologische Gemeinschaftspraxis am Seelberg, 70372 Stuttgart, Germany.
Guy ArnoldKlinik für Neurologie Sindelfingen, Krankenhaus Sindelfingen-Böblingen, 71065 Sindelfingen, Germany.
Tobias WächterHertie-Institute for Clinical Brain Research, Department of Neurodegenerative Diseases, 72076 Tübingen, Germany.

Funding

Merz Pharmaceuticals N.A.
6 · The paper itself

Abstract

objectiveThe effects of botulinum toxin injections (BoNT) on health-related quality of life along the complex spectrum of spasticity needs further characterization to guide practitioners in a real-life therapeutic environment.

methodsIn this study, we analyzed 50 consecutive and unselected patients with spasticity before and four weeks after re-injection of botulinum toxin. Health-related quality of life in terms of the EuroQol (EQ) as well as further motor and non-motor characteristics were assessed.

resultsBoNT improved the EQ visual analog scale (EQ VAS). In addition, state of health and pain maxima improved. The EQ VAS improvement correlated with pre-injection characteristics of the EQ VAS and life satisfaction in the "movement disorders" domain.

conclusionEQ VAS is sensitive for monitoring HR-QoL outcomes in an unselected real life observational cohort. This study may inform future studies intended to validate prediction variables that could inform on HR-QoL effects of BoNT treatment in spasticity.

Indexed as

Quality of LifeAcetylcholine Release InhibitorsAdultAgedBotulinum ToxinsFemaleHealth StatusHumansMaleMiddle AgedMuscle SpasticityPatient SatisfactionProspective StudiesSurveys and QuestionnairesTime FactorsTreatment OutcomeAcetylcholine Release InhibitorsBotulinum Toxinsbotulinum toxindystoniaparesisquality of lifespasticity

Identifiers

PMID32375388
PMCPMC7291043

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.